RE: Times article26 Dec 2021 11:17
Islandgirl - one problem is that a treatment which keeps people out of hospital has to be easily and quickly administered to possibly millions of people, ie: a low cost pill. (I keep thinking about the 'SNG needs a fire to fight' comment).
I like to view the drugs landscape as being split into four broad categories:
1. Protection against catching COVID: vaccines, which will continue to evolve as new variants emerge
2. Minimising symptoms and the odds of hospitalisation: low cost, high volume drugs (pills) - this is an increasingly crowded marketplace which SNG (or a version of it - a simple inhaler?) may one day play a role. The SG016 'Home Trial' leg was too small and unsupported/promoted in the UK to produce great results. The US-funded ACTIV-2 Phase 3 global trial may produce positive results which, given the high cost of a hospital stay, may be cost-justified by their health insurance firms. Not in the UK though.
3. Preventing hospitalised patients on oxygen from getting worse, reducing odds of death, reducing their stay and restoring them to full health more effectively: this seems to be our most promising and exciting market, especially as other contenders have been dropping out of trials due to poor efficacy
4. Preventing patients in ICU with severe symptoms from dying: Dexamethasone is filling this role; SNG is not currently being trialled for this late stage.
I konw this is a very crude summary of a subject in which I am certainly not an expert. But as a long-term SNG investor it helps me to keep a sense of persepective and positioning. From all that I have read, a really interesting possibility is that people might be 'profiled' to establish their specific immune response capability prior to contracting an infection, so that the most appropriate treatment and dosage could be rapidly given. Today, we are using a 'one size fits all' approach. Tomorrow, maybe, treatments might be accurately targeted to suit each patient.
Tim